E6/E7 Functional Differences among Two Natural Human Papillomavirus 18 Variants in Human Keratinocytes

Imagem de Miniatura
Arquivos
art_NUNES_E6E7_Functional_Differences_among_Two_Natural_Human_Papillomavirus_2021.PDF (3.33 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
LINO, Vanesca de Souza
BOCCARDO, Enrique
Citação
VIRUSES-BASEL, v.13, n.6, article ID 1114, 17p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
It is suggested that HPV-18 variants from the A lineage have higher oncogenic potential compared to B variants. Some studies show uneven distribution of HPV-18 variants in cervical adenocarcinomas and squamous cell carcinomas. Regarding HPV-18 variants' functions, the few studies reported focus on E6, and none were performed using natural host cells. Here, we immortalized primary human keratinocytes (PHKs) with E6/E7 of HPV-18 A1 and B1 sublineages and functionally characterized these cells. PHK18A1 reached immortalization significantly faster than PHK18B1 and formed a higher number of colonies in monolayer and 3D cultures. Moreover, PHK18A1 showed greater invasion ability and higher resistance to apoptosis induced by actinomycin-D. Nevertheless, no differences were observed regarding morphology, proliferation after immortalization, migration, or epithelial development in raft cultures. Noteworthy, our study highlights qualitative differences among HPV-18 A1 and B1 immortalized PHKs: in contrast to PHK18A1, which formed more compact colonies and spheroids of firmly grouped cells and tended to invade and migrate as clustered cells, morphologically, PHK18B1 colonies and spheroids were looser, and migration and invasion of single cells were observed. Although these observations may be relevant for the association of these variants with cervical cancer of different histological subtypes, further studies are warranted to elucidate the mechanisms behind these findings.
Palavras-chave
HPV-18, oncogenic potential, molecular variant, cell transformation, immortalization
URI
https://observatorio.fm.usp.br/handle/OPI/41369
Referências
  1. Arias-Pulido H, 2005, VIROLOGY, V338, P22, DOI 10.1016/j.virol.2005.04.022
  2. Asadurian Y, 2007, J MED VIROL, V79, P1751, DOI 10.1002/jmv.20978
  3. Berumen J, 2001, JNCI-J NATL CANCER I, V93, P1325, DOI 10.1093/jnci/93.17.1325
  4. BLANTON RA, 1991, AM J PATHOL, V138, P673
  5. Boccardo E, 2004, VIROLOGY, V328, P233, DOI 10.1016/j.virol.2004.07.026
  6. Boccardo E, 2010, CARCINOGENESIS, V31, P521, DOI 10.1093/carcin/bgp333
  7. Brant AC, 2019, GENOMICS, V111, P1853, DOI 10.1016/j.ygeno.2018.12.008
  8. Burk RD, 2003, CANCER RES, V63, P7215
  9. Cabeca TK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010198
  10. Chen AA, 2015, J VIROL, V89, P10680, DOI 10.1128/JVI.01747-15
  11. Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072565
  12. Contreras-Paredes A, 2009, VIROLOGY, V383, P78, DOI 10.1016/j.virol.2008.09.040
  13. De Boer MA, 2005, INT J CANCER, V114, P422, DOI 10.1002/ijc.20727
  14. De la Cruz-Hernandez E, 2005, J GEN VIROL, V86, P2459, DOI 10.1099/vir.0.80945-0
  15. de Sanjose S, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky045
  16. DiMaio D, 2006, ADV VIRUS RES, V66, P125, DOI 10.1016/S0065-3527(06)66003-X
  17. Estevao D, 2019, BBA-GENE REGUL MECH, V1862, P153, DOI 10.1016/j.bbagrm.2019.01.001
  18. Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000
  19. Fragoso-Ontiveros V, 2012, VIROLOGY, V432, P81, DOI 10.1016/j.virol.2012.05.029
  20. Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
  21. Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109
  22. HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990
  23. Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174
  24. Kleeff J, 2000, INT J CANCER, V86, P399, DOI 10.1002/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G
  25. Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0
  26. Lace MJ, 2009, J VIROL, V83, P11784, DOI 10.1128/JVI.01370-09
  27. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  28. Lizano M, 1997, Gac Med Mex, V133 Suppl 1, P43
  29. Lopez-Saavedra A, 2009, ARCH VIROL, V154, P747, DOI 10.1007/s00705-009-0362-4
  30. Maddox P, 1999, J CLIN PATHOL, V52, P41, DOI 10.1136/jcp.52.1.41
  31. MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169
  32. MUNGER K, 1989, J VIROL, V63, P4417
  33. ONG CK, 1993, J VIROL, V67, P6424, DOI 10.1128/JVI.67.11.6424-6431.1993
  34. Perez S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104678
  35. Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134
  36. Pim D, 2010, APMIS, V118, P471, DOI 10.1111/j.1600-0463.2010.02618.x
  37. Pista A, 2007, J MED VIROL, V79, P1889, DOI 10.1002/jmv.21002
  38. Rajendran V, 2018, METHODS MOL BIOL, V1692, P89, DOI 10.1007/978-1-4939-7401-6_8
  39. Richard C, 2010, ONCOGENE, V29, P3435, DOI 10.1038/onc.2010.93
  40. Schiffman M, 2010, CANCER RES, V70, P3159, DOI 10.1158/0008-5472.CAN-09-4179
  41. Sichero L, 2005, J INFECT DIS, V191, P739, DOI 10.1086/427825
  42. Sichero L, 2007, INT J CANCER, V120, P1763, DOI 10.1002/ijc.22481
  43. Sichero L, 2012, VIROLOGY, V432, P127, DOI 10.1016/j.virol.2012.06.011
  44. Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998
  45. Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006
  46. Termini L, 2018, CURR TOP MED CHEM, V18, P246, DOI 10.2174/1568026618666180410125850
  47. Vazquez-Vega S, 2013, J MED VIROL, V85, P1215, DOI 10.1002/jmv.23568
  48. Wang QQ, 2019, INT J CANCER, V144, P1619, DOI 10.1002/ijc.31876
  49. WRIGHT SC, 1994, FASEB J, V8, P654
  50. Xi LF, 2007, CANCER EPIDEM BIOMAR, V16, P4, DOI 10.1158/1055-9965.EPI-06-0670

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03